S2 EP25 - GLP-1, Ozempic, and the Supplement Industry: Hype, Hope, or Harm? - The Bioactive Breakdown

In this conversation, experts discuss the implications ofGLP-1 receptor agonists like Ozempic in the context of weight loss and the supplement industry. They explore the mechanisms of GLP-1, the importance of diet and exercise, and the challenges faced by individuals using thesemedications. The panelists emphasize the need for a comprehensive approach to obesity, including dietary changes and physical activity, while also addressingthe role of natural products and emerging research in metabolic health. They conclude with thoughts on the future of weight management and the importance of consumer education in navigating the supplement landscape.

Please see the links below for more information on our guests’ companies.

• Dr. Jacqueline Jacques, ND – Wellness Industry Expert, obesity specialist, vocal critic of “natural Ozempic” claimso https://www.bariatricadvantage.com/o https://www.mvpnutra.net/o https://shop.myeq.com/

• Jim Ayres – CEO of Kelker Pharma, product development and contract manufacturing leadero https://kelkerpharma.com/

• Dr. Luc Maes, ND – Founder of KAIBAE, expert in gut–metabolic axis, polyphenols, and microbiome scienceo https://maescenter.com/o https://www.baobabingredients.com/o https://gokaibae.com/

• Michael Bengivenga – SVP, New Business Development Vitaworks, experienced in brand and commercial development in the supplement spaceo https://vitaworksusa.com/